Core Points - The event "Inheriting Good Ancient Recipes, Inheriting Good Family Traditions" by Baiyunshan Xiaochaihu marks its 8th anniversary and aims to promote positive family values in Shandong [1][2] - The event was live-streamed on social media platforms, achieving over 1.14 million views [2] - Baiyunshan Xiaochaihu has been actively involved in social responsibility initiatives, including donations exceeding 10 million yuan for various causes [7] Group 1 - The event was held in Jinan, Shandong, and is part of a broader initiative to spread love and positive energy through family values [1][2] - Baiyunshan Xiaochaihu has organized this event across 12 provinces over the past eight years, sharing over 200 stories of good family traditions [6][15] - The event featured participation from various local leaders and organizations, highlighting community collaboration [6][21] Group 2 - Baiyunshan Xiaochaihu announced a new initiative called "One More Penny of Care," where a portion of sales will be donated to public welfare projects [16] - The company received a gold award at the 50th Geneva International Exhibition for its innovative Xiaochaihu granules, showcasing its commitment to modernizing traditional medicine [15] - The upgraded national standard for Xiaochaihu granules has been included in the 2025 edition of the Chinese Pharmacopoeia, reflecting industry recognition [15] Group 3 - The event included performances and cultural displays, emphasizing the rich cultural heritage of Shandong [24][27] - Families sharing their good family traditions were recognized, reinforcing the importance of family values in society [20][30] - Baiyunshan Xiaochaihu plans to continue its "Finding Good Family Traditions" initiative to enrich cultural life and promote social virtues [30]

Core Viewpoint - A recent network meta-analysis published in a core journal indicates that Baiyunshan Gushen Dingchuan Wan shows superior efficacy in improving clinical effectiveness and forced vital capacity (FVC) for treating stable chronic obstructive pulmonary disease (COPD) [2][3][9]. Group 1: Research Findings - The study reviewed randomized controlled trials of oral traditional Chinese medicine for stable COPD treatment, utilizing a network meta-analysis approach [6][7]. - Results demonstrated that five types of oral traditional Chinese medicines significantly improved treatment outcomes with a high safety profile and minimal adverse reactions [8][9]. - Among the evaluated medicines, Gushen Dingchuan Wan exhibited the best performance in enhancing clinical effectiveness and FVC [9]. Group 2: Treatment Mechanism - Gushen Dingchuan Wan is formulated based on principles of warming the kidneys and lungs, and strengthening the spleen to alleviate symptoms in COPD patients with kidney and lung qi deficiency [10][13]. - The medicine aims to improve lung function and promote respiratory muscle recovery, thereby enhancing patient vitality and quality of life [11][14]. Group 3: Clinical Guidelines and Recommendations - Gushen Dingchuan Wan is included in several authoritative guidelines and consensus recommendations for COPD treatment, such as the "Clinical Application Guidelines for Integrated Traditional and Western Medicine in COPD (2024)" [16][17]. - Its inclusion in these guidelines supports its further application and promotion in the treatment of related diseases [20].

Core Viewpoint - The 2025 China Clinical Oncology Annual Progress Seminar (BOC) and Best of ASCO® 2025 China will be held on July 4-5, 2025, focusing on significant research findings from the ASCO annual meeting and enhancing the influence of Chinese scholars in the international arena [2]. Group 1: Clinical Research Findings - The IV phase clinical study led by Professor Liu Zhigang on "Baiyunshan Nasopharyngeal Detox Granules" demonstrated significant improvements in severe nasal secretion symptoms and reduced the incidence of severe oral mucositis in nasopharyngeal cancer patients undergoing radiotherapy, indicating a promising innovative treatment option [2]. - The study also reported improvements in symptoms such as throat pain and dryness, showcasing good safety profiles for the treatment [2]. Group 2: Background and Development - Radiotherapy remains the primary curative method for nasopharyngeal cancer, with approximately 90% of patients experiencing adverse reactions like radiation-induced oral mucositis, which severely impacts treatment outcomes and quality of life [3]. - Baiyunshan and Huang Zhong Medicine have invested in clinical research since 2022 to address radiation-induced damage in the nasopharyngeal area, with the project supported by prominent experts in the field [3][4]. - Baiyunshan Nasopharyngeal Detox Granules, developed in collaboration with Sun Yat-sen University Cancer Center and Guangzhou Pharmaceutical Group, is clinically used for chronic inflammation and increased secretion symptoms post-radiotherapy [4].

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年6月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 廣州白雲山醫藥集團股份有限公司 （「本公司」） 呈交日期: 2025年7月2日 I. 法定/註冊股本變動 1. 股份分類 普通股 股份類別 H 於香港聯交所上市 (註1) 是 證券代號 (如上市) 00874 說明 香港聯交所上市 H 股 法定/註冊股份數目 面值 法定/註冊股本 上月底結存 219,900,000 RMB 1 RMB 219,900,000 增加 / 減少 (-) RMB 本月底結存 219,900,000 RMB 1 RMB 219,900,000 | 2. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 600332 | 說明 | | 於上海證券交易所 （「上交所」）上市之A股 | | | | | | | | 法定/ ...

廣州白雲山醫藥集團股份有限公司 董事會 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 關連交易進展公告 向白雲山生物增資 茲提述廣州白雲山醫藥集團股份有限公司（「本公司」）日期為2025年5月28日之公告（「該公告」）,內容 有關向白雲山生物增資之關連交易。除另有界定外，本公告所用詞彙與該公告所界定者具有相同涵 義。 董事會欣然宣佈於2025年6月30日，本公司與廣藥創投基金、廣州老字號基金、廣藥產投基金、國資 併購基金、拜迪生物及白雲山生物訂立了增資協議，增資協議於同日正式生效。增資協議的主要條 款並無任何變更。增資協議的主要條款及本次增資詳情載於該公告。 本次增資完成後，本公司於白雲山生物的直接及間接持股比例維持不變，仍為50.00%。白雲山生物 仍為本公司之附屬公司，其財務業績繼續納入本公司之合併報表。 中國廣州，2025年6月30日 於本公告日，本公司董事會成員包括執行董事李小軍先生、程寧女士、程洪進先生、唐和平先生與 黎洪先生，及獨立非執 ...

Group 1 - The board of directors of Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. held its 26th meeting of the 9th session on June 23, 2025, with all 9 directors participating and voting [1][2] - The meeting approved the proposal to add new members to the specialized committees of the board, with a unanimous vote of 9 in favor, 0 against, and 0 abstentions [1] - The newly appointed members to the specialized committees include Mr. Li Xiaojun, Mr. Cheng Hongjin, and Mr. Tang Heping, effective from the date of the board's approval until the end of the current board's term [1][2] Group 2 - The composition of the Strategic Development and Investment Committee now includes Mr. Li Xiaojun as the chairperson and members Mr. Li Hong, Mr. Chen Yajin, and Ms. Sun Baoqing [1] - The Nomination and Remuneration Committee is chaired by Mr. Huang Min, with members including Mr. Chen Yajin, Ms. Sun Baoqing, and the newly added Mr. Cheng Hongjin [2] - The Budget Committee is chaired by Mr. Chen Yajin, with members including Ms. Cheng Ning, Mr. Huang Min, Mr. Huang Longde, and the newly added Mr. Tang Heping [2]

Core Viewpoint - Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. has approved its 2024 annual equity distribution plan during the shareholders' meeting held on June 3, 2025, emphasizing its commitment to shareholder returns [1] Summary by Relevant Sections Equity Distribution Plan - The equity distribution plan includes a record date of June 18, 2025, and the ex-dividend date and cash dividend payment date are both set for June 19, 2025 [1] - The distribution is targeted at A-share shareholders registered with China Securities Depository and Clearing Corporation Limited in Shanghai as of the close of trading on the record date [1] Taxation Details - Individual shareholders and securities investment funds holding shares for over one year are exempt from personal income tax, while those holding for one month to one year are taxed at a rate of 10%, and those holding for less than one month are taxed at 20% [1] - Qualified Foreign Institutional Investors (QFII) and investors through the Shanghai-Hong Kong Stock Connect are subject to a 10% tax rate [1] Shareholder Engagement - The dividend plan reflects the company's focus on returning value to shareholders and aligns with relevant tax policy requirements [1] - Investors are advised to pay attention to the record date and tax treatment details to ensure the smooth realization of their rights [1]

Core Viewpoint - Baiyunshan has received approval for the registration of Tadalafil tablets, positioning it as a successor to its existing product, Jin Ge (Sildenafil) [1][3]. Group 1: Product Overview - Tadalafil is a PDE5 inhibitor similar to Sildenafil, primarily used for treating erectile dysfunction (ED) [1][3]. - Tadalafil has advantages over Sildenafil, including lower dosage, longer half-life, and less impact from high-fat meals and alcohol [3]. Group 2: Market Dynamics - The domestic market for Tadalafil has not performed as well as Sildenafil, facing intense competition and a dual market structure of hospital and retail sales [3][4]. - In 2024, Tadalafil's sales in public hospitals were only RMB 186 million, indicating a limited market size [7]. - The introduction of centralized procurement policies has compressed the market ceiling for Tadalafil in hospitals [4]. Group 3: Competitive Landscape - In 2024, Tadalafil's total sales in hospitals were RMB 142 million, with the original drug, Cialis, holding a 30.14% market share, while generic competitors have gained significant volume [7][11]. - The retail market for Tadalafil is much larger, with total sales of approximately RMB 2.906 billion in 2024, split between offline and online pharmacies [14]. - The online retail market is highly fragmented, with various brands competing for market share [20]. Group 4: Challenges and Future Outlook - Baiyunshan faces challenges in establishing Tadalafil as a blockbuster product due to the competitive landscape and lack of first-mover advantage [23]. - The company is also exploring other male health medications, such as Dapoxetine, but the overall market for these products is limited [24]. - Jin Ge's sales and revenue have declined in 2024, indicating potential saturation in its market [24][25].

Major Events - JiuTai Rural Commercial Bank (06122) plans to sell 78.51% stake in HuanShan HuiMin Village Bank for 40.4 million yuan [1] - Vanke Enterprises (02202) intends to receive a loan of up to 3 billion yuan from its major shareholder, Shenzhen Metro Group [1] - China Gas Holdings (08246) signed a memorandum of understanding with the Lao Ministry of Industry and Commerce to explore cooperation in developing fuel and natural gas supply networks in Laos [1] - Miniso Group (09896) is conducting a preliminary assessment on the potential spin-off listing of its trendy toy business operated under the "TOP TOY" brand [1] - Baiyunshan Pharmaceutical (00874) subsidiary received approval from the National Medical Products Administration for the drug registration certificate of Tadalafil tablets (2.5mg, 5mg) [1] - Huaxing Capital Holdings (01911) portfolio company Circle successfully listed on the New York Stock Exchange, marking the first IPO milestone in the global stablecoin sector [1] - China National Nuclear Corporation (01763) plans to initiate its first irradiation station cooperation project in Peru [1] Operating Performance - Yuexiu Property (00123) reported a cumulative contract sales amount of approximately 50.7 billion yuan in the first five months, an increase of about 26.5% year-on-year [1] - China Overseas Land & Investment (00688) recorded a cumulative property sales amount of approximately 90.4 billion yuan in the first five months, a decrease of 11.1% year-on-year [1] - Shimao Group (00813) reported a cumulative contract sales total of 11.2 billion yuan in the first five months, a decrease of 18.71% year-on-year [1] - Zhongliang Holdings (02772) achieved a cumulative contract sales amount of approximately 5.37 billion yuan in the first five months, a decrease of 33.38% year-on-year [1] - GAC Group (02238) experienced a year-on-year decline in May's automobile production by 8.16% and a sales drop of 24.80% [1] - Poly Property Group (00119) achieved a contract sales amount of approximately 21.8 billion yuan in the first five months, an increase of 3.81% year-on-year [1] - New天绿色能源 (00956) completed a power generation volume of approximately 7.29 million megawatt-hours in the first five months, an increase of 10.86% year-on-year [1]

Group 1 - The company has received the drug registration certificate for Tadalafil tablets (2.5mg, 5mg) from the National Medical Products Administration [1][2] - Tadalafil is a phosphodiesterase type 5 (PDE5) inhibitor primarily used for treating erectile dysfunction (ED) [2] - The original manufacturer of Tadalafil is Eli Lilly, which received approvals in the EU and the US in November 2002 and November 2003, respectively, and in China in December 2004 [2] Group 2 - The company submitted the drug registration application for Tadalafil on January 2, 2024, and received acceptance on January 24, 2024 [2] - In 2024, the sales figures for Tadalafil tablets in Chinese public hospitals, urban pharmacies, and online pharmacies were approximately RMB 185.73 million, RMB 1.294 billion, and RMB 1.61182 billion, respectively [2] - The company has invested approximately RMB 2.54 million and RMB 4.30 million in the R&D of 2.5mg and 5mg Tadalafil tablets, respectively [3] Group 3 - The approval of Tadalafil tablets enhances the company's product offerings in the male medication sector, potentially increasing its market competitiveness [3] - The company plans to commence production in accordance with relevant requirements and market demand [3]